MEVOPUR Chemical Foaming Agents Application Bulletin_JP_1.18-1 MEVOPUR™ CFA (化学発泡剤) 医療機器・医薬品包装用 * 原材料はQbD（Quality by Design）原則で選定し、リスク評価を 行っています。 規制対応 • • • 評価試験*: - ISO 10993-1 - USP および (Class VI) - 欧州薬局方 モノグラフ 3.1.3/ 3.1.5 (ポリオ レフィン系包装材料) - USP (ポリエチレン) - ICH Q3Dに準拠した元素不純物分析 DMF（Type III）および Device Master File 登 録済み 米国FDAおよびEUの食品接触規格 軽量化 ヘルスケア用途に制限ありー下記参照詳しくはAvientにお問い合わせください。 1)30日以上、人体組織または体液に暴露すること。

Microsoft Word - Terms and Conditions of Sale for Indonesia (English 12-17-24) TERMS AND CONDITIONS These Terms and Conditions govern the sale of Products to another (“Buyer”) by Avient Corporation and its affiliates (“Seller”). 1. If (i) Buyer is in default of performance of its obligations towards Seller and fails to provide adequate assurance of Buyer’s performance before the date of scheduled delivery; or (ii) if Seller has reasonable doubts with respect to Buyer’s performance of its obligations and Buyer fails to provide to Seller adequate assurance of Buyer’s performance before the date of scheduled delivery and in any case within thirty (30) days of Seller’s demand for such assurance; or (iii) if Buyer becomes insolvent or unable to pay its debts as they mature, or goes into liquidation or any bankruptcy proceeding shall be instituted by or against Buyer or if a trustee or receiver or administrator is appointed for all or a substantial part of the assets of Buyer or if Buyer makes any assignment for the benefit of its creditors; or (iv) in case of non- compliance of Buyer with any law, statute ordinance, regulation, code or standard in the Republic of Indonesia concerning the trade, export or re-export of products, services, data or technology (“Laws and Standards”), then Seller may by notice in writing to Buyer, without prejudice to any of its other rights: (a) demand return and take repossession of any delivered Products which have not been paid for and all costs relating to the recovery of the Products shall be for the account of Buyer; and/or (b) suspend its performance or terminate its order confirmation for pending delivery of Products unless Buyer makes such payment for Products on a cash in advance basis or provides adequate assurance of such payment for Products to Seller.

PolyOne Corporation Page 1 PolyOne Investor Presentation Goldman Sachs Basic Materials Conference May 2016 PolyOne Corporation Page 2 Forward-Looking Statements  In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Adjusted EPS is calculated as follows: Adjusted EPS 2006Y* 2007Y* 2008Y* 2009Y* 2010Y 2011Y 2012Y 2013Y 2014Y 2015Y Net income (loss) attributable to PolyOne common shareholders $ 130.9 $ 40.9 $ (417.0) $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 Joint venture equity earnings, after tax (68.5) (26.1) (20.8) (19.0) (14.7) (3.7) - - - - Special items, after tax(1) (51.2) 10.7 457.2 (75.9) (72.5) (72.8) 36.2 32.6 90.5 28.9 Adjusted net income $ 11.2 $ 25.5 $ 19.4 $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 Diluted shares 92.8 93.1 92.7 93.4 96.0 94.3 89.8 96.5 93.5 88.7 Adjusted EPS $ 0.12 $ 0.27 $ 0.21 $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 Adjusted EPS Q1 2009* Q2 2009* Q3 2009* Q4 2009* Q1 2010 Q2 2010 Q3 2010 Q4 2010 Net income attributable to PolyOne common shareholders $ 3.3 $ 1.3 $ 51.3 $ 50.8 $ 20.1 $ 44.7 $ 0.1 $ 87.6 Joint venture equity earnings, after tax (8.2) (5.8) (3.0) (2.0) (0.5) (4.5) (6.2) (3.5) Special items, after tax(1) (10.2) 9.2 (36.9) (38.0) (3.8) (22.1) 25.4 (72.0) Adjusted net (loss) income $ (15.1) $ 4.7 $ 11.4 $ 10.8 $ 15.8 $ 18.1 $ 19.3 $ 12.1 Diluted shares 92.2 93.5 93.9 94.4 95.3 96.3 96.3 97.4 Adjusted EPS $ (0.16) $ 0.05 $ 0.12 $ 0.11 $ 0.17 $ 0.19 $ 0.20 $ 0.12 Adjusted EPS Q1 2011 Q2 2011 Q3 2011 Q4 2011 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Net income attributable to PolyOne common shareholders $ 106.0 $ 23.1 $ 16.0 $ 8.3 $ 15.3 $ 18.4 $ 19.4 $ 0.2 Joint venture equity earnings, after tax (3.7) - - - - - - - Special items, after tax(1) (81.3) 1.3 2.8 4.4 6.2 8.9 5.4 15.7 Adjusted net income $ 21.0 $ 24.4 $ 18.8 $ 12.7 $ 21.5 $ 27.3 $ 24.8 $ 15.9 Diluted shares 96.4 95.5 94.0 91.9 90.7 90.7 90.2 90.5 Adjusted EPS $ 0.22 $ 0.26 $ 0.20 $ 0.14 $ 0.24 $ 0.30 $ 0.28 $ 0.18 2 Adjusted EPS Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 Net income (loss) attributable to PolyOne common shareholders $ 11.2 $ 38.6 $ 23.2 $ 21.0 $ 29.4 $ 30.9 $ 32.3 $ (14.6) Special items, after tax(1) 17.7 (2.0) 12.3 4.6 12.5 17.4 13.1 47.5 Adjusted net income $ 28.9 $ 36.6 $ 35.5 $ 25.6 $ 41.9 $ 48.3 $ 45.4 $ 32.9 Diluted shares 92.8 99.1 98.1 97.2 95.7 94.3 93.1 91.3 Adjusted EPS $ 0.31 $ 0.37 $ 0.36 $ 0.26 $ 0.44 $ 0.51 $ 0.49 $ 0.36 Adjusted EPS Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Net income attributable to PolyOne common shareholders $ 30.2 $ 66.8 $ 44.5 $ 3.1 $ 39.1 Special items, after tax(1) 11.4 (15.9) 3.0 30.4 9.1 Adjusted net income $ 41.6 $ 50.9 $ 47.5 $ 33.5 $ 48.2 Diluted shares 90.1 89.8 88.4 86.6 85.5 Adjusted EPS $ 0.46 $ 0.57 $ 0.54 $ 0.39 $ 0.56 Adjusted operating margin is calculated as follows: Adjusted operating margin Q1 2009* Q2 2009* Q3 2009* Q4 2009* YTD 2009* Q1 2010 Q2 2010 Q3 2010 Q4 2010 YTD 2010 Operating Income $ 9.9 $ 17.1 $ 57.9 $ 52.2 $ 137.1 $ 32.3 $ 58.6 $ 42.0 $ 26.3 $ 159.2 Special items (1) (1.3) 4.6 (27.5) (24.5) (48.7) - (14.5) 5.5 4.2 (4.8) Joint venture equity earnings (12.8) (9.0) (4.8) (3.1) (29.7) (0.8) (7.1) (9.7) (5.5) (23.1) Adjusted operating (loss) income $ (4.2) $ 12.7 $ 25.6 $ 24.6 $ 58.7 $ 31.5 $ 37.0 $ 37.8 $ 25.0 $ 131.3 Sales $ 463.4 $ 496.5 $ 548.3 $ 552.5 $ 2,060.7 $ 604.0 $ 666.2 $ 650.7 $ 585.3 $ 2,506.2 Operating Margin (0.9)% 2.6% 4.7% 4.5% 2.8% 5.2% 5.6% 5.8% 4.3% 5.2% Adjusted operating margin Q1 2011 Q2 2011 Q3 2011 Q4 2011 YTD 2011 Q1 2012 Q2 2012 Q3 2012 Q4 2012 YTD 2012 Operating income (loss) $ 173.4 $ 42.4 $ 33.4 $ (46.2) $ 203.0 $ 37.4 $ 43.3 $ 43.5 $ 13.3 $ 137.5 Special items (1) (127.2) 2.7 4.9 72.9 (46.7) 8.5 11.8 8.3 25.3 53.9 Joint venture equity earnings (5.7) - - - (5.7) - - - - - Adjusted operating income $ 40.5 $ 45.1 $ 38.3 $ 26.7 $ 150.6 $ 45.9 $ 55.1 $ 51.8 $ 38.6 $ 191.4 Sales $ 682.8 $ 723.4 $ 694.0 $ 609.2 $ 2,709.4 $ 745.5 $ 756.6 $ 707.7 $ 651.0 $ 2,860.8 Operating Margin 5.9% 6.2% 5.5% 4.4% 5.6% 6.2% 7.3% 7.3% 5.9% 6.7% 3 Adjusted operating margin Q1 2013 Q2 2013 Q3 2013 Q4 2013 YTD 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 YTD 2014 Operating income (loss) $ 40.5 $ 80.7 $ 61.6 $ 48.7 $ 231.5 $ 56.4 $ 49.4 $ 63.6 $ (14.3) $ 155.1 Special items (1) 16.6 (5.2) 10.8 7.8 30.0 22.9 39.8 22.0 80.2 164.9 Adjusted operating income $ 57.1 $ 75.5 $ 72.4 $ 56.5 $ 261.5 $ 79.3 $ 89.2 $ 85.6 $ 65.9 $ 320.0 Sales $ 801.1 $ 1,037.6 $ 1,008.9 $ 923.6 $ 3,771.2 $ 1,002.3 $ 1,005.5 $ 958.4 $ 869.3 $ 3,835.5 Operating Margin 7.1% 7.3% 7.2% 6.1% 6.9% 7.9% 8.9% 8.9% 7.6% 8.3% Adjusted operating margin Q1 2015 Q2 2015 Q3 2015 Q4 2015 YTD 2015 Q1 2016 Operating income $ 70.1 $ 80.3 $ 69.2 $ 31.3 $ 250.9 $ 71.3 Special items (1) 9.3 11.9 18.7 31.4 71.3 13.8 Adjusted operating income $ 79.4 $ 92.2 $ 87.9 $ 62.7 $ 322.2 $ 85.1 Sales $ 873.1 $ 887.1 $ 841.6 $ 775.8 $ 3,377.6 $ 847.0 Operating Margin 9.1% 10.4% 10.4% 8.1% 9.5% 10.0% Adjusted gross margin is calculated as follows: (In millions) Twelve Months Ended December 31, 2015 Gross margin - GAAP $ 681.5 Special items in gross margin(1) 39.7 Gross margin before special items $ 721.2 Specialty operating income mix percentage is calculated as follows: Platform operating income mix percentage 2005* 2010* 2015 Color, Additives and Inks $ 4.3 $ 37.7 $ 135.4 Specialty Engineered Materials 0.4 49.7 79.6 Designed Structures and Solutions - - 13.8 Specialty Platform $ 4.7 $ 87.4 $ 228.8 Performance Products and Solutions 75.7 54.0 57.4 Distribution 19.5 42.0 68.0 Joint ventures 91.9 18.9 — Corporate and eliminations (51.5) (27.7) (103.3) Operating income GAAP $ 140.3 $ 174.6 $ 250.9 Less: Corporate operating expense 51.5 27.7 103.3 Operating income excluding Corporate $ 191.8 $ 202.3 $ 354.2 Specialty platform operating mix percentage 2% 43% 65% 4 Adjusted EBITDA and net debt to adjusted EBITDA is calculated as follows: (In millions) Q2 2015 Q3 2015 Q4 2015 Q1 2016 Trailing Twelve Months Ended March 31, 2016 Income (loss) from continuing operations, before income taxes $ 63.4 $ 51.4 $ (0.4) $ 57.0 $ 171.4 Interest expense, net 16.2 16.2 15.6 14.6 62.6 Depreciation and amortization 25.0 28.3 25.9 27.2 106.4 Special items, impact on income (loss) from continuing operations before income taxes(1) 11.9 18.6 47.8 13.6 91.9 Accelerated depreciation included in special items (0.2) (4.3) (1.6) (2.8) (8.9) Adjusted EBITDA $ 116.3 $ 110.2 $ 87.3 $ 109.6 $ 423.4 Short-term and current portion of long-term debt $ 18.6 Long-term debt 1,174.3 Less: Cash and cash equivalents (155.4) Net Debt 1,037.5 Net Debt/TTM Adjusted EBITDA 2.5 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principal, discontinued operations or the related resegmentation 1) Special items are a non-GAAP financial measure and are used to determine adjusted earnings.

Asia SEM Healthcare Product Selection Guide_CN3.31-1 埃万特特种 工程材料-针对 医疗保健行业 产品选购指南 应用于医疗器械的材料及其对患者安全所产生的影响需要仔细斟 酌。 TRILLIANT™ HC8920 TRILLIANT™ HC2020 Trilliant™ HC2020 材料描述 基料 共聚酯 Trilliant™ HC8910/8920 聚酮/ABS共混物 Trilliant™ HC2120 Tritan Trilliant™ HC3120 PC Trilliant™ HC5210 PP Trilliant™ HC6010 PA6 Trilliant™ HC6610 PA66 Trilliant™ GRV-NP-110-W PA12 应用： TRILLIANT™ HC热塑性塑料 • • • • • 作为FR PC/ABS、FR PC/PET和FR COPE的 耐化学性替代品，在各种颜色的应用中，其 阻燃等级在1.5mm和0.75mm厚度下分别可 达到UL 94黄卡V-0级和V-1级。 ST5200-8030 ESD BK001 1 5 27 52 1980 42 E3 ST5200-8035 ESD BK001 1 20 22 37 1460 150 E3 应用： TRILLIANT™ HC 导电配方 • • • • • 导电性一致确保可重复使用部件的性能，同时 最大限度减少导电性不一致引发的相关问题 高流量和易加工性有利于薄壁零件填充和多腔 工具，从而缩短循环时间并且降低每单位部件 的成本 优异的耐用性在减少破裂的同时，还可降低由 此产生的报废相关成本 不易形成飞边，外观得到改善，且可减少吸头 内外的液体滞留，从而提高准确度并降低交叉 污染的可能性 通过高强度生产的部件，其刚性和耐翘曲性也 更高，再次最大限度降低因报废产生的相关成 本 • 导电移液吸头 +86.21.60284888 www.avient.com 版权所有©2022 埃万特公司。

1. एथिक्स हॉटलाइन https://www.Avient.com/company/policies-and- governance/ethics-hotline टेलीफोन 1-877-228-5410 7 विषय 2021 संशोधित एकाधिकार व्यापार विरोधी नीति mailto:ethics.officer%40avient.com? subject= http://avient.ethicspoint.com http://www.Avient.com/company/policies-and-governance/ethics-hotline http://www.Avient.com/company/policies-and-governance/ethics-hotline 1.

Domaines potentiellement délicats en matière de lois antitrust 1. Ligne d’assistance Éthique https://www.Avient.com/company/policies-and- governance/ethics-hotline Téléphone sur la ligne d’assistance Éthique 1-877-228-5410 7 Contenu Politique antitrust révisée 2021 mailto:ethics.officer%40avient.com? subject= http://avient.ethicspoint.com http://www.Avient.com/company/policies-and-governance/ethics-hotline http://www.Avient.com/company/policies-and-governance/ethics-hotline 1.

Our filings are available to the public at the SEC’s website at http://www.sec.gov. A breach of any of these covenants would result in a default under the agreements. In the event of any default, our lenders could elect to declare all amounts borrowed under the agreements, together with accrued interest thereon, to be due and payable.

Investor Day P O L Y O N E I N V E S T O R P R E S E N T A T I O N M A R C H 2 0 1 8 F O R W A R D L O O K I N G S T A T E M E N T S PolyOne Corporation 2 In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. T H E N E W P O L Y O N E : A S P E C I A L T Y G R O W T H C O M P A N Y  Growing leadership position in attractive markets  Innovation, technology and service are differentiators  Capital management is a strength: Record-setting cash generation to continue for years  Expand ROIC while increasing invested capital  Proven acquisition strategy with robust pipeline  Commercial investments are fueling momentum and generating organic growth S E G M E N T H I G H L I G H T S PolyOne Corporation 17 C O L O R , A D D I T I V E S & I N K S E N D M A R K E T S & S O L U T I O N S PolyOne Corporation 18 Solid Colorants Performance Additives Screen Printing Inks Liquid Colorants Packaging 27% Industrial 14% Textiles 12% Building & Construction 10% Wire & Cable 10% Transportation 8% Consumer 7% Healthcare 6% Electrical & Electronics 3% Appliance 3% Operating Income & MarginRevenue by Region C O L O R , A D D I T I V E S & I N K S 2 0 1 7 R E V E N U E | $ 8 9 3 M I L L I O N $4 $25 $104 $139 0.9% 5.5% 12.2% 15.5% 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 14.0% 16.0% 18.0% 20 30 40 50 60 70 80 90 100 110 120 130 140 150 2005 2009 2013 2017 PolyOne Corporation 19 Europe 32% United States 46% Asia 15% Canada 1% Mexico 4% Brazil 2% (in millions) S P E C I A L T Y E N G I N E E R E D M A T E R I A L S E N D M A R K E T S & S O L U T I O N S PolyOne Corporation 20 Engineered Formulations Advanced Composites Thermoplastic Elastomers Consumer 20% Transportation 19% Electrical & Electronics 15% Wire & Cable 13% Healthcare 11% Industrial 8% Packaging 7% Appliance 4% Building & Construction 3% S P E C I A L T Y E N G I N E E R E D M A T E R I A L S Revenue by Region Operating Income & Margin 2 0 1 7 R E V E N U E | $ 6 2 4 M I L L I O N PolyOne Corporation 21 $21 $57 $78 0.1% 5.1% 9.3% 12.5% 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 14.0% 20 30 40 50 60 70 80 90 2005 2009 2013 2017 Europe 28% United States 48% Asia 22% Canada 2% (in millions) P E R F O R M A N C E P R O D U C T S & S O L U T I O N S E N D M A R K E T S & S O L U T I O N S PolyOne Corporation 22 Specialty Vinyl Solutions Healthcare Formulations Smart Device Materials Flame Retardant Polymers Building & Construction 30% Industrial 18% Transportation 16% Wire & Cable 15%Appliance 7% Packaging 5% Consumer 5% Electrical & Electronics 3% Healthcare 1% Mexico 5% United States 77% Latin America 2% Canada 16% P E R F O R M A N C E P R O D U C T S & S O L U T I O N S Operating Income & MarginRevenue by Region 2 0 1 7 R E V E N U E | $ 7 2 1 M I L L I O N $40 $33 $56 $77 4.6% 3.6% 7.2% 10.7% 0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 14.0% 16.0% 0 10 20 30 40 50 60 70 80 90 100 2005 2009 2013 2017 PolyOne Corporation 23 (in millions) D I S T R I B U T I O N E N D M A R K E T S & S U P P L I E R S PolyOne Corporation 24 Transportation 23% Healthcare 22% Industrial 18% Consumer 15% Appliance 7% Electrical & Electronics 6% Building & Construction 4% Packaging 3% Wire & Cable 2% $20 $25 $63 $73 2.9% 4.0% 5.9% 6.3% 0.0% 1.0% 2.0% 3.0% 4.0% 5.0% 6.0% 7.0% 15 25 35 45 55 65 75 2005 2009 2013 2017 Operating Income & Margin (in millions) 2017 Revenue | $1.2 Billion http://www.polyone.com/Pages/VariationRoot.aspx http://www.polyone.com/Pages/VariationRoot.aspx T A R G E T E N D M A R K E T S & A P P L I C A T I O N E X A M P L E S PolyOne Corporation 25 Thermally Conductive Technologies Chemical Resistant Technologies Polymer Colorants Elastomeric Grips and Handles Structural Composites Antimicrobial Technologies Anti-Counterfeiting Technologies Target End Markets… Healthcare Catheter Technologies Under-hood Components Target End Markets… Automotive Interior Structural Components Sound & Vibration Management Roof Systems Air Management Electronics and Cameras Lighting Exterior / Interior Trim Braces & Brackets Fasteners Seals & Flaps Target End Markets… Consumer Thermally Conductive Components Polymer Colorants Elastomeric Grips and Handles Structural Composite Components Oxygen Scavenger Technologies Laser Marking Additives Antistatic Technologies UV Light Barrier Technologies Cap & Closure Colorants Process Optimization Technologies Antioxidant Technologies Density Modified Technologies Target End Markets… Packaging  Impart weight, sound and metallic finish to caps and closures for cosmetics and spirits applications  Elevate quality and prestige perceptions among high-end consumers  Eliminate time and cost associated with secondary operations and assembly Luxury Packaging GravitechTM Density Modified Polymers  Eliminate costs by increasing pigment density  Enhance color performance without altering form and formulation  Increase design capabilities by reducing weight and layer thickness Optimize Color Usage OnColorTM Super Concentrates  Inhibit microbial growth on polymer surfaces  Enhance value or products and devices  Highly versatile concentrate with the ability to be incorporated into a wide variety of products Combat Bacteria Formation WithStandTM Antimicrobial Technology  Durable, long-lasting products stand up to the most aggressive disinfectants  Minimize environmental stress cracking and discoloration  One of the broadest medically approved polymer and colorant portfolios Medical Device Housings Chemically Resistant Engineered Polymers Color & Design Services  Greater control of color development and supply chain  Work across entire design process from concept to commercialization  Inspire creativity in the use of polymer materials, colors, and effects  Innovative brand differentiation  Faster development timelines Outdoor Applications  Leading provider of high performance specialty materials for the recreational and sports & leisure industry  Well positioned across all segments to address market needs  Metal to Polymer Conversion  Lightweighting  Thermal Management  Impact Performance  ColorMatrix Fiber Colorant Solutions  Proprietary advanced liquid color formulations and equipment enable greater efficiency and productivity  Eliminates aqueous dyeing and its associated wastewater treatment  Solid Color Concentrates  Extrusion-spun fibers colored via solid masterbatch Fiber Colorants  High flame retardancy to meet strict UL standards  Greater processing and design flexibility  Specialized additives provide long term color stability  Diffusive lens materials improve light dispersion Smart Home Devices ResilienceTM Vinyl Solutions 1 Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to PolyOne common shareholders, adjusted earnings per share (EPS) attributable to PolyOne common shareholders and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) to assess performance and allocate resources because senior management believes that these measures are useful in understanding current profitability levels and that current levels may serve as a base for future performance. Adjusted EPS attributable to PolyOne common shareholders is calculated as follows: 2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016 2017 Net income from continuing operations attributable to PolyOne common shareholders $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 Joint venture equity earnings, after tax (19.0) (14.7) (3.7) — — — — — — Special items, before tax(1) (48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 Special items, tax adjustments(1) (27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) Adjusted net income from continuing operations attributable to PolyOne common shareholders $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation

Das örtliche Avient-Unternehmen der Gerichtsbarkeit, bei dem Sie sich um eine Stelle bewerben, wird hinsichtlich Ihrer persönlichen Daten als Verantwortlicher der Datenverarbeitung fungieren. 1. Datum des Inkrafttretens: 1. August 2020 mailto:PRIVACY.OFFICER@AVIENT.COM https://privacyportal.onetrust.com/webform/b25cf7b1-a93a-4d26-8c84-ceda4d0ae91b/e180cbe4-d1b9-49bd-b621-cb5f6a0f42cb https://privacyportal.onetrust.com/webform/b25cf7b1-a93a-4d26-8c84-ceda4d0ae91b/e180cbe4-d1b9-49bd-b621-cb5f6a0f42cb mailto:PRIVACY.OFFICER@AVIENT.COM

Our filings are available to the public at the SEC’s website at http://www.sec.gov. A breach of any of these covenants would result in a default under the agreements. In the event of any default, our lenders could elect to declare all amounts borrowed under the agreements, together with accrued interest thereon, to be due and payable.